Navigation Links
Vicor Technologies announces results of PD2i analysis of MUSIC trial data
Date:5/19/2010

Boca Raton, FL May 19, 2010 David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced the initial results of a study designed to analyze data from the Merte Subita en Insufficiencia Cardiaca (MUSIC) Trial using its PD2i algorithm and software. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i nonlinear algorithm and software. Vicor develops diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

The study, titled "Prognostic Significance of Point Correlation Dimension Algorithm (PD2i) in Chronic Heart Failure," was conducted under a collaborative agreement with the University of Rochester and the Catalan Institute of Cardiovascular Sciences in Barcelona. The goal of the study was to evaluate the ability of Vicor's PD2i nonlinear algorithm to predict cardiac events in the 537 chronic heart failure patients enrolled in the MUSIC Trial; MUSIC Trial participants were followed for an average period of 44 months. The conclusion of the University of Rochester researchers who conducted the study is that the PD2i nonlinear algorithm and software is predictive of total mortality, cardiac death, and heart failure death in patients with left ventricular ejection fraction of less than or equal to 35%. With a P value of 0.004 the study results are highly statistically significant.

Commenting on the study and its results, Wojciech Zareba, M.D. Ph.D. the Principal Investigator at the University of Rochester said, "These results are of major importance for risk stratifying heart failure patients who are eligible for therapy with an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with defibrillator (CRT-D). Currently, only about 30-40% of heart failure patients eligible for this therapy receive devices. Testing heart failure patients using the PD2i should enhance risk stratification and motivate physicians to implant these devices in ICD/CRT-D eligible patients with abnormal PD2i test results."

"We're extremely pleased with the results achieved in this study. Researchers from the University of Rochester and Vicor scientists are studying these initial results to determine whether the resulting data will support a 510(k) submission to the Food and Drug Administration (FDA) for a marketing claim. What we have achieved may broaden the market for the PD2i Analyzer as a diagnostic that will significantly contribute to cardiologists in their assessment of treatment options for heart failure patients," stated Mr. Fater.


'/>"/>

Contact: Robin Schoen
schoenpr@comcast.net
215-504-2122
Vicor Technologies, Inc.
Source:Eurekalert

Related biology news :

1. NIH awards UC $9 million grant to improve patient point-of-care technologies
2. Patent Issued for e-Smart Technologies, Inc.s First Biometric Match-on-Card Technology
3. Titanium Group to Showcase Products and Technologies in Prestigious Government Seminar
4. e-Smart Technologies Responds to Press Release Issued By IDsmart LLC
5. e-Smart Technologies, Inc. Responds to Information Subpoenas From Securities & Exchange Commission
6. e-Smart(R) Technologies, Inc., Announces Next Generation Superthin Polyimide Flexible Circuit Biometric Super Smart Card(TM) card, the i am(TM) Card.
7. Material Technologies Holds First Electrochemical Fatigue Sensor Training for Private Inspection Firms
8. e-Smart(R) Technologies Delivers Its New Super Smart Card(TM) in South Korea.
9. e-SMART Technologies Continues Delivery of Its New Super SMART Card in South Korea
10. Phoenix Technologies and Atmel Collaborate to Create Next-Generation Security Solutions for PCs
11. Atmel and Phoenix Technologies Collaborate to Create Next-generation Security Solutions for PCs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology: